APLIF Stock - Appili Therapeutics Inc.
Unlock GoAI Insights for APLIF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $100,443 | $827,407 | $334,177 | $1.39M | N/A |
| Gross Profit | $100,443 | $827,407 | $334,177 | $1.39M | $-14,836 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-190,839 | $-2,162,790 | $-7,775,815 | $-23,615,446 | $-16,295,839 |
| Net Income | $-2,624,692 | $-3,780,910 | $-9,243,014 | $-25,118,299 | $-14,325,112 |
| Net Margin | -2613.1% | -457.0% | -2765.9% | -1806.2% | N/A |
| EPS | $-0.02 | $-0.03 | $-0.08 | $-0.38 | $-0.24 |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Visit WebsiteEarnings History & Surprises
APLIFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 12, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.01 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-0.00 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.01 | — | — |
Q2 2024 | Jun 25, 2024 | $-0.01 | $-0.01 | 0.0% | = MET |
Q1 2024 | Feb 13, 2024 | $-0.01 | $-0.00 | +90.5% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.01 | $-0.01 | -27.6% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.01 | $-0.01 | -62.9% | ✗ MISS |
Q2 2023 | Jun 23, 2023 | $-0.01 | $-0.02 | -35.2% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-0.02 | $-0.02 | -25.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.01 | $-0.01 | -63.1% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.02 | $-0.02 | -17.6% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-0.08 | $-0.06 | +25.0% | ✓ BEAT |
Q1 2022 | Feb 14, 2022 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.07 | $-0.14 | -100.0% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q2 2021 | Jun 24, 2021 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q1 2021 | Feb 15, 2021 | $-0.03 | $-0.05 | -83.8% | ✗ MISS |
Latest News
Frequently Asked Questions about APLIF
What is APLIF's current stock price?
What is the analyst price target for APLIF?
What sector is Appili Therapeutics Inc. in?
What is APLIF's market cap?
Does APLIF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to APLIF for comparison